Tranilast

Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM) . Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects[1]. Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells[2].

Product Specifications

CAS Number

[53902-12-8]

Product Name Alternative

MK-341; SB 252218

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Angiotensin Receptor; Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology; Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Tranilast.html

Purity

99.95

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(O)C1=CC=CC=C1NC(/C=C/C2=CC=C(OC)C(OC)=C2)=O

Molecular Formula

C18H17NO5

Molecular Weight

327.33

Precautions

H302, H315, H319, H335

References & Citations

[1]K Ikai , et al. Inhibitory Effect of Tranilast on Prostaglandin D Synthetase. Biochem Pharmacol. 1989 Aug 15;38 (16) :2673-6.|[2]Sara Darakhshan, et al. Tranilast Enhances the Anti-Tumor Effects of Tamoxifen on Human Breast Cancer Cells in Vitro. J Biomed Sci. 2013 Oct 21;20 (1) :76.|[3]E A Capper, et al. Modulation of Human Monocyte Activities by Tranilast, SB 252218, a Compound Demonstrating Efficacy in Restenosis. J Pharmacol Exp Ther. 2000 Dec;295 (3) :1061-9.|[4]M Isaji , et al. Tranilast Inhibits the Proliferation, Chemotaxis and Tube Formation of Human Microvascular Endothelial Cells in Vitro and Angiogenesis in Vivo. Br J Pharmacol. 1997 Nov;122 (6) :1061-6.|[5]K Miyazawa , et al. Tranilast Antagonizes Angiotensin II and Inhibits Its Biological Effects in Vascular Smooth Muscle Cells. Atherosclerosis. 1996 Apr 5;121 (2) :167-73.